ADDICTION
TREATMENT
RANKINGS
Get Help Now
MEDICATIONS

Medication access is a core capability, not an optional amenity

FDA-approved medications for opioid use disorder include buprenorphine, methadone, and naltrexone. Programs should explain which options they provide or continue, how they decide, and how access is protected after discharge.

Updated September 3, 20262 primary sourcesEvidence-led decision guide
Prepared byAddiction Treatment Rankings Editorial Team
Last reviewedSeptember 3, 2026
Evidence base2 primary sources
Clinical reviewNot individually claimed
Read the review policy
Quiet medically monitored detox room prepared for withdrawal assessment and nursing support
A representative care setting. Verify the exact staff, service, schedule, and capability at the location you are considering.
A CLEAR DECISION PATHMove from question to verified action
01UnderstandStart with the direct answer and its safety limits.02CompareTest broad claims against capability and evidence.03AskUse the exact questions and documentation workflow.04VerifyConfirm the source, date, location, and unresolved gaps.
Explore rankings and treatment guidesStates, cities, substances, treatment types, insurance, and Learn
01

The short answer

Buprenorphine, methadone, and naltrexone are FDA-approved for opioid use disorder. They differ in pharmacology, initiation, regulation, dosing, access, and patient fit. A qualified clinician should discuss benefits, risks, prior treatment, current opioid use, withdrawal status, medical factors, preferences, and practical access.

A program that requires every patient to stop an effective medication, offers only one option without clinical explanation, or cannot ensure continuation after discharge creates a material risk. Ask whether medication can begin or continue immediately and who will prescribe the next dose.

02

Questions that change the decision

Use the same questions for every program. Record the exact location, source, answer, date checked, and any conflict that remains unresolved.

  1. 01

    Confirm which medications are initiated and continued at the exact location.

  2. 02

    Ask who prescribes and how quickly evaluation occurs.

  3. 03

    Verify induction, dosing, monitoring, and emergency procedures.

  4. 04

    Ask whether counseling is required as a condition of medication access.

  5. 05

    Secure the post-discharge prescriber and medication supply before transition.

03

Compare the claim with evidence

A precise claim is not automatically a verified fact. The table below separates a useful starting source from the remaining question.

Claim or decisionStrong starting evidenceWhat still needs confirmation
Medication-assisted treatmentExact medications, prescriber, and service processWhether access is available now at this location
Medication-free philosophyClinical rationale and informed alternativesRisk of withdrawal, return to use, and overdose
Continuity after dischargeConfirmed prescriber and appointmentBridge supply and response to delays
04

Limits, safety, and next steps

Medication choice and initiation require individualized clinical care. Do not start, stop, or change medication based on a directory page. Abrupt discontinuation or loss of tolerance can create serious risk.

Availability, staffing, payer participation, and clinical capability can change. Recheck time-sensitive facts with the exact facility, clinician, regulator, and health plan before admission or payment.

05

Scenario: medication is allowed, but no continuing prescriber is available

A residential facility continues buprenorphine during the stay but discharges the patient with no confirmed prescriber for the next dose. The program can accurately say medication is permitted, yet the transition creates an avoidable interruption risk.

Verify initiation and continuation separately. Ask who prescribes, which formulations are available, how dosing is handled, what happens during hospitalization or transfer, and whether the next clinician has accepted the patient before discharge.

Why this example matters

The decision is not resolved by a brand label or a single reassuring answer. It is resolved by matching the claim to the exact person, service, place, source, and date, then keeping any conflict visible until a qualified source resolves it.

06

What a decision-ready answer must show

Strong evidence is cumulative. A useful answer connects the governing record or clinical framework to current operations and then states what remains uncertain. One source rarely establishes every part of a treatment decision.

  1. 01
    Clinical choice

    A qualified clinician considers indication, risks, current substances, prior response, medical factors, and patient preference.

  2. 02
    Real access

    The exact location can initiate or continue the medication without an avoidable delay.

  3. 03
    Continuity

    The next prescriber, dose, pharmacy, payment route, records, and response to disruption are confirmed.

A missing layer does not always mean a program or plan is unsafe. It means the conclusion should remain qualified. The correct editorial response is to describe the gap, identify the source that could resolve it, and avoid upgrading an unverified statement into a recommendation.

07

What the latest national evidence adds

National figures describe a population, not the quality of one facility or the right plan for one person. They are included to show scale and access gaps. The year, population, measurement, and limitation travel with each number.

Fewer than 1 in 5

people with opioid use disorder receive medication treatment

NIDA reports that methadone, buprenorphine, and naltrexone are FDA-approved for opioid use disorder and that medication reduces overdose-death risk, yet fewer than 20 percent of people with opioid use disorder receive these medications.

National Institute on Drug Abuse
44,564

estimated overdose deaths involving opioids in 2025

CDC estimated that opioid-involved overdose deaths declined from 55,296 in 2024 to 44,564 in 2025. Deaths may involve multiple drugs, and the sum of drug-specific categories does not equal the total overdose count.

CDC 2025 provisional overdose release

Interpretation limit: These estimates cannot rank a treatment center, predict an individual outcome, or substitute for local capacity, payer, regulator, and clinical checks. They explain why the decision deserves careful verification.

08

How to turn this guide into a documented decision

Write the decision in one sentence: medications for opioid use disorder: what to verify. Add who the decision concerns, the deadline, and the safety condition that would change the timeline. Then keep that question separate from a facility sales conversation so the answer does not drift toward whichever service happens to be available.

Create a claim log for this exact topic. Record the wording, physical location, legal entity, service, source, representative, and date checked. Mark each claim supported, contradicted, time-sensitive, or unresolved. Compare the result with the person's clinical needs, medication continuity, transportation, housing, family responsibilities, language access, cost, network status, and next-care handoff.

  1. Define the decision.Record the person, service, location, deadline, and immediate safety threshold.
  2. Capture the claim.Use the exact wording instead of paraphrasing a promise into a stronger statement.
  3. Match the source.Identify whether the source proves authorization, clinical guidance, current operations, coverage, price, or only marketing.
  4. Check freshness.Reconfirm capacity, staffing, medication, network, authorization, and transportation close to the action date.
  5. Keep conflicts visible.Do not average contradictory records into a confident conclusion. Name the conflict and the source needed to resolve it.
  6. Confirm the handoff.Name the receiving clinician or program, appointment, medication bridge, travel plan, and fallback if the next step fails.

The final note should distinguish three things: what is supported, what is a reasonable inference, and what is still unknown. That distinction makes the conclusion easier to verify and safer to rely on. A concise answer with explicit limits is more useful than a confident paragraph built from mixed evidence.

09

What most comparisons miss

A useful guide adds the details that disappear in a generic definition. For medications for opioid use disorder: what to verify, the following blind spots can change the answer even when the broad claim sounds correct.

Permitted does not mean available

A policy allowing medication does not establish that a qualified prescriber can start it, the pharmacy can supply it, the payer will cover it, or the program will continue it without interruption. Verify each operational step separately.

The next dose is a quality measure

Medication continuity should be tested at admission, transfer, hospitalization, discharge, travel, and pharmacy closure. The plan needs a prescriber, dose, date, payment route, records, transportation, and a response if any link fails.

Preference belongs in the evidence

Effectiveness and risk matter, but so do prior response, daily routine, travel, stigma, pregnancy, pain, other medication, work, caregiving, and patient preference. A medication plan that cannot be followed is not fully compared.

These details are deliberately separated from provider rankings. They define what evidence a future ranking would need, but they do not create a score or endorse a facility by themselves. A ranking should remain pending when a material blind spot is unresolved.

10

Questions to use in the real conversation

Use the wording below with a facility, health plan, clinician, regulator, employer, or other responsible source. Ask one question at a time, record the exact answer, and request the document or primary record that supports it. The purpose is not to make the call adversarial. It is to make the answer specific enough to verify.

  1. 01
    Can the medication be started or continued at this exact location?

    A permissive policy is not enough. Identify the clinician, evaluation, timing, formulations, pharmacy, payment route, and operating hours.

  2. 02
    How are the options compared with the patient?

    The answer should address indication, prior response, preference, risks, interactions, pregnancy, pain, schedule, travel, and practical access.

  3. 03
    What happens if the patient arrives on the medication already?

    Verify dose confirmation, records, storage, administration, missed doses, hospital transfer, and whether the program imposes unsupported discontinuation.

  4. 04
    Which services are recommended with medication and which are required?

    Clinical support can be valuable, but vague participation rules should not create an avoidable interruption in evidence-based medication care.

  5. 05
    Who provides the next dose after discharge or transfer?

    Record the accepted prescriber or program, appointment, dose, pharmacy, transportation, insurance, records, and response to a delay.

  6. 06
    How are effectiveness, adverse effects, and patient goals reviewed?

    Medication management should include follow-up, shared decisions, safety monitoring, and a documented response when the plan is not working.

Minimum decision record

Question: Medications for Opioid Use Disorder: What to Verify

Record: exact claim, person or entity, physical location, service, source, representative, date checked, supported conclusion, remaining conflict, next action, and the date the fact must be rechecked.

Decision rule: do not treat no answer, a general brand statement, or a promised future referral as proof of current capability. Mark the item unresolved and identify who has authority to resolve it.

11

How to resolve conflicting answers

Classify the disagreement before choosing a source. Match identity by legal operator and address, narrow scope to the exact service and location, preserve the date, and ask the party with authority over that fact to resolve it.

  1. Match identity and scope

    Do not combine a brand, facility, billing entity, license, or service until the address and operating relationship match.

  2. Match authority and date

    Use regulators for authorization, clinicians for medical fit, health plans for benefits, and facilities for current operations. Recheck time-sensitive claims near the action date.

  3. Keep unresolved conflicts visible

    State both findings, identify the missing record or decision-maker, and keep the conclusion provisional rather than averaging the conflict away.

Sources used for this guide

These sources establish the general framework for medications for opioid use disorder: what to verify. They do not prove current admission, capacity, staffing, price, network status, or patient fit at an individual facility.

  • FDA: Medications for opioid use disorderfda.gov - review the publication date, definitions, population, scope, and linked underlying evidence before applying the source to a local decision.
  • NIDA: Medications for opioid use disordernida.nih.gov - review the publication date, definitions, population, scope, and linked underlying evidence before applying the source to a local decision.

The resulting note should be understandable without the original phone call. Another reviewer should be able to see what was asked, what each source established, why one source had authority for a particular fact, and what remains unknown. That is the standard for information that can support a recommendation or citation.

12

Frequently asked questions

These answers state the general rule first, then preserve the condition that could change it. They are written for quick extraction, but the evidence and safety limits elsewhere on this page still apply.

Which medications are FDA approved for opioid use disorder?

Buprenorphine, methadone, and naltrexone are FDA approved. They differ in mechanism, initiation, regulation, dosing, access, and patient fit.

Should counseling be required before medication begins?

Medication decisions should be clinical and patient centered. Counseling can help, but lack of counseling participation should not be used casually to create a dangerous medication gap.

What is medication continuity?

It means the patient can receive the correct next dose through a confirmed prescriber or program, with records, pharmacy access, payment, transportation, and a response to delays.

13

What to recheck before relying on this answer

Clinical guidance, laws, payer rules, facility operations, and local resources change on different schedules. Reopen the primary source when the decision is time-sensitive. For medical or withdrawal questions, a current assessment matters more than the page date. For insurance, confirm the exact plan and service. For a facility, confirm the exact address and operating entity.

Do not use publication length as a proxy for authority. The useful test is whether the guide answers the real question, links the source that supports each important claim, explains the evidence boundary, and gives the reader a reproducible next action. Where national data or broad guidance cannot resolve a local fact, this page says so instead of filling the gap with a generic recommendation.

Editorial review should occur after a material guideline or rule change, when a linked primary source changes, when new national data alters the context, or when readers identify a conflict. Time-sensitive facility and payer facts should be checked again at the point of action even when this guide has been reviewed recently.

Bottom lineA medication claim is incomplete until initiation, continuation, and the next dose are all operationally real.
14

Primary sources and next checks

Use these sources to verify the clinical, regulatory, coverage, or safety framework. Recheck dates and location-specific details before acting.

  1. 01
  2. 02

Editorial scope: This guide supports comparison and verification. It does not diagnose a condition, determine a safe withdrawal plan, guarantee coverage, or replace advice from a qualified clinician.